1. Home
  2. IGC vs VSEE Comparison

IGC vs VSEE Comparison

Compare IGC & VSEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IGC
  • VSEE
  • Stock Information
  • Founded
  • IGC 2005
  • VSEE 2008
  • Country
  • IGC United States
  • VSEE United States
  • Employees
  • IGC N/A
  • VSEE N/A
  • Industry
  • IGC Biotechnology: Pharmaceutical Preparations
  • VSEE
  • Sector
  • IGC Health Care
  • VSEE
  • Exchange
  • IGC Nasdaq
  • VSEE NYSE
  • Market Cap
  • IGC 29.4M
  • VSEE 29.3M
  • IPO Year
  • IGC N/A
  • VSEE N/A
  • Fundamental
  • Price
  • IGC $0.31
  • VSEE $1.26
  • Analyst Decision
  • IGC Strong Buy
  • VSEE Strong Buy
  • Analyst Count
  • IGC 2
  • VSEE 1
  • Target Price
  • IGC $3.88
  • VSEE $5.00
  • AVG Volume (30 Days)
  • IGC 392.1K
  • VSEE 114.9K
  • Earning Date
  • IGC 02-18-2025
  • VSEE 03-18-2025
  • Dividend Yield
  • IGC N/A
  • VSEE N/A
  • EPS Growth
  • IGC N/A
  • VSEE N/A
  • EPS
  • IGC N/A
  • VSEE N/A
  • Revenue
  • IGC $1,236,000.00
  • VSEE $8,064,925.00
  • Revenue This Year
  • IGC N/A
  • VSEE $76.10
  • Revenue Next Year
  • IGC $18.34
  • VSEE $64.83
  • P/E Ratio
  • IGC N/A
  • VSEE N/A
  • Revenue Growth
  • IGC 1.64
  • VSEE 37.45
  • 52 Week Low
  • IGC $0.26
  • VSEE $1.12
  • 52 Week High
  • IGC $0.91
  • VSEE $33.08
  • Technical
  • Relative Strength Index (RSI)
  • IGC 52.84
  • VSEE N/A
  • Support Level
  • IGC $0.26
  • VSEE N/A
  • Resistance Level
  • IGC $0.34
  • VSEE N/A
  • Average True Range (ATR)
  • IGC 0.02
  • VSEE 0.00
  • MACD
  • IGC 0.01
  • VSEE 0.00
  • Stochastic Oscillator
  • IGC 65.88
  • VSEE 0.00

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

About VSEE VSEE HEALTH INC

VSee Health Inc is a telehealth software platform. VSee's telemedicine solution, offering a fast, secure text + video collaboration app HIPAA messenger, and fully customizable virtual waiting rooms and clinics, is a complete telehealth platform that fits into any workflow. The VSee proprietary technology platform and modular software solution enable users to plug and play telehealth services with end-to-end encrypted video streaming integrated with patient metrics, electronic medical records, and other sensitive data, with multiple other interactive functionalities. The company's products include VSee Clinic, VSee Messenger, VSee APIs, VSee Remote patient monitoring, VSee Telehealth Staffing.

Share on Social Networks: